NVCR News and Press, NovoCure Limited From 04/28/22

Quarterly net revenues of $137.5 million with 80% gross margin Entering a transformational period with multiple clinical catalysts expected in near-term Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2022. Novocure is a globa...

NovoCure (NASDAQ:NVCR) is scheduled to announce Q1 earnings results on Thursday, April 28th, before market open. The consensus EPS Estimate is -$0.19 and the consensus Revenue Estimate is $134.29M (-0.3% Y/Y). Over the last 1 year, NVCR has beaten EPS estimates 25% of the time and has be...

Healthcare is arguably the most regulated industry in the stock market. Before a company is allowed to market a drug to the public, it has to pay for expensive clinical trials that prove a drug is both safe and effective. So getting an approval from the Food and Drug Administration (FDA) is...

Governor Sununu and Novocure leadership delivered keynote remarks, celebrating the construction of Novocure’s new flagship facility in Portsmouth, NH Today, Governor Chris Sununu (R-NH) joined Novocure for a ceremonial event commemorating the start of construction of ...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Small cap stocks had a rough ride during the first quarte...

Investing in biotechnology companies is both difficult and incredibly exciting. Watching as a company goes through the regulatory approval process, from a fledgling early-stage clinical trial biotech to an industry juggernaut, can be exhilarating. While positive outcomes aren't guarante...

The following slide deck was published by NovoCure Limited in conjunction with this event. For further details see: NovoCure (NVCR) Investor Presentation - Slideshow

Novocure (NASDAQ: NVCR) today announced 19 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2022, to be held in New Orleans from April 8 to April 13, 2022. The research described in the presentation...

With its novel Tumor Treating Fields therapy that uses electrical pulses to treat cancer, Novocure (NASDAQ: NVCR) could offer new hope to patients and physicians. In this Motley Fool Live segment from The Pharma & Biotech Show, recorded on March 23 , Fool.com contributor...

One group stands out as an interesting and potentially dramatically undervalued area of the market in the wake of the pandemic and its historical footprint: Medical device stocks. The healthcare system has been forever changed by the pandemic, which accelerated several core healthcare industr...